



AMERICAN BOARD OF PSYCHIATRY AND NEUROLOGY, INC.

SUBSPECIALTY CERTIFICATION EXAMINATION IN
NEURODEVELOPMENTAL DISABILITIES
2009 Content Outline

200 questions	Percent
I. Normal development	5%
A. Cognitive	
B. Motor	
C. Behavior	
D. Language/communication	
E. Developmental theory	
F. Psychometrics	
II. Neurogenetics	10%
A. Chromosomal disorders	
B. Genetic disorders	
C. Metabolic/degenerative abnormalities	
D. Dysmorphology	
E. Genetic counseling	
F. Treatment	
G. Prevention	
III. Cognitive disorders (mental retardation)	15%
A. Diagnostic criteria, including diagnostic testing	
B. Etiology/epidemiology	
C. Natural history	
D. Correlation with functional status, associated deficits	
E. Treatment	
1. Pharmacotherapy	
2. Medical/surgical therapy	
3. Habilitation, including PT/OT, speech therapy, education, behavioral therapy	
F. Prevention	
IV. Cognitive disorders (learning disabilities)	10%
A. Diagnostic criteria, including diagnostic testing	
B. Etiology/epidemiology	
C. Natural history	
D. Correlation with functional status, associated deficits	
E. Treatment	
1. Pharmacotherapy	



AMERICAN BOARD OF PSYCHIATRY AND NEUROLOGY, INC.

2. Medical/surgical therapy
 3. Habilitation, including PT/OT, speech therapy, education, behavioral therapy
- F. Prevention
- V. Communication disorders, e.g., autistic disorder, developmental language disorders** **15%**
- A. Diagnostic criteria, including diagnostic testing
 - B. Etiology/epidemiology
 - C. Natural history
 - D. Correlation with functional status, associated deficits
 - E. Treatment
 1. Pharmacotherapy
 2. Medical/surgical therapy
 3. Habilitation, including PT/OT, speech therapy, education, behavioral therapy
 - F. Prevention
- VI. Neurobehavioral disorders, e.g., ADHD, obsessive-compulsive disorder, oppositional defiant disorder, childhood disintegrative disorder, Tourette disorder** **10%**
- A. Diagnostic criteria, including diagnostic testing
 - B. Etiology/epidemiology
 - C. Natural history
 - D. Correlation with functional status, associated deficits
 - E. Treatment
 1. Pharmacotherapy
 2. Medical/surgical therapy
 3. Habilitation, including PT/OT, speech therapy, education, behavioral therapy
 - F. Prevention
- VII. Motor disabilities, e.g., static and progressive encephalopathies, cerebral palsy, neuromuscular disorders, minor neuromotor dysfunction** **10%**
- A. Diagnostic criteria, including diagnostic testing
 - B. Etiology/epidemiology
 - C. Natural history
 - D. Correlation with functional status, associated deficits
 - E. Treatment
 1. Pharmacotherapy



AMERICAN BOARD OF PSYCHIATRY AND NEUROLOGY, INC.

- 2. Medical/surgical therapy
 - 3. Habilitation, including PT/OT, speech therapy, education, behavioral therapy
 - F. Prevention
- VIII. Visual and auditory impairments** **5%**
- A. Diagnostic criteria, including diagnostic testing
 - B. Etiology/epidemiology
 - C. Natural history
 - D. Correlation with functional status, associated deficits
 - E. Treatment
 - 1. Pharmacotherapy
 - 2. Medical/surgical therapy
 - 3. Habilitation, including PT/OT, speech therapy, education, behavioral therapy
 - F. Prevention
- IX. Neurodevelopmental disorders associated with major medical conditions, e.g., spina bifida, severely and profoundly disabled, low-birth-weight infants, multiple congenital anomalies** **7.5%**
- A. Diagnostic criteria, including diagnostic testing
 - B. Etiology/epidemiology
 - C. Natural history
 - D. Correlation with functional status, associated deficits
 - E. Treatment
 - 1. Pharmacotherapy
 - 2. Medical/surgical therapy
 - 3. Habilitation, including PT/OT, speech therapy, education, behavioral therapy
 - F. Prevention
- X. Rehabilitation, e.g., traumatic brain and spinal cord injuries, near-drowning** **5%**
- A. Diagnostic criteria, including diagnostic testing
 - B. Etiology/epidemiology
 - C. Natural history
 - D. Correlation with functional status, associated deficits
 - E. Treatment
 - 1. Pharmacotherapy
 - 2. Medical/surgical therapy



AMERICAN BOARD OF PSYCHIATRY AND NEUROLOGY, INC.

	3.	Habilitation, including PT/OT, speech therapy, education, behavioral therapy	
	F.	Prevention	
XI.		Counseling, advocacy, and ethics, including research ethics	7.5%
	A.	Persistent vegetative states/brain death	
	B.	Legislative issues, e.g., ADA	
	C.	Community resources	
	D.	Family-centered approaches to NDD patients	
TOTAL			100%